Los Angeles Capital Management LLC Purchases 5,173 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Posted by Geri Gentry on Jun 7th, 2026

Los Angeles Capital Management LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.4% during the fourth quarter, HoldingsChannel reports. The fund owned 100,508 shares of the biopharmaceutical company’s stock after buying an additional 5,173 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $77,579,000 as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in REGN. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. Entrust Financial LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $32,000. Caitlin John LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.1%

REGN stock opened at $635.45 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company’s 50 day moving average is $706.93 and its 200 day moving average is $742.16. The stock has a market cap of $67.18 billion, a price-to-earnings ratio of 15.48, a price-to-earnings-growth ratio of 1.40 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 1-year low of $485.00 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same period in the prior year, the business earned $8.22 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Barclays reduced their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Finally, Canaccord Genuity Group reduced their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $792.65.

Get Our Latest Stock Report on REGN

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.